Tissue-engineered heart valve prostheses: 'State of the heart'

Regenerative Medicine

Volumn 3, Issue 3, 2008, Pages 399-419

  Migneco, Francesco ^a   Hollister, Scott J ^a   Birla, Ravi K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biomaterials; Biomechanics; Bioreactors; Fibroblast; Heart valve; Regenerative medicine; Tissue engineering; Valve pathology; Valve physiology

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; NOTCH RECEPTOR; POLYMER; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; BIOMATERIAL;

ALLOGRAFT; AORTA VALVE STENOSIS; AUTOGRAFT; BIOPROSTHESIS; BIOREACTOR; BONE MARROW CELL; CALCIFICATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART VALVE; HEART VALVE PROSTHESIS; HUMAN; IMMUNE RESPONSE; LEYDIG CELL; MESENCHYME CELL; PATHOGENESIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROSTHESIS MATERIAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE; TISSUE ENGINEERING; UPREGULATION; VALVULAR HEART DISEASE; ANIMAL; AORTA VALVE; AUDIOVISUAL EQUIPMENT; BIOLOGICAL MODEL; CHEMISTRY; CYTOLOGY; EQUIPMENT DESIGN; METHODOLOGY; OSTEOBLAST; PATHOLOGY; PROSTHESIS; STEM CELL;

ANIMALS; AORTIC VALVE; BIOCOMPATIBLE MATERIALS; BIOREACTORS; ENDOTHELIAL CELLS; EQUIPMENT DESIGN; HEART VALVE PROSTHESIS; HUMANS; MODELS, ANATOMIC; MODELS, BIOLOGICAL; OSTEOBLASTS; POLYMERS; PROSTHESIS DESIGN; STEM CELLS; TISSUE ENGINEERING;

EID: 48849112033     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.3.399     Document Type: Review

References (161)

1. Rosamond W, Flegal K, Furie K et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25-e146 (2008).
2. Hammermeister KE, Sethi GK, Henderson WG, Oprian C, Kim T, Rahimtoola S: A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthests. Veterans Affairs Cooperative Study on Vaivular Heart Disease. N. Engl. J. Med. 328(18), 1289-1296 (1993).
3. Vongpatanasin W, Hillis LD, Lange RA: Prosthetic heart valves. N. Engl. J. Med. 335(6), 407-416 (1996).
4. Schmidt CE, Baier JM: Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. Biomaterials 21(22), 2215-2231 (2000).
5. Mayer JE Jr: Uses of homograft conduits for right ventricle to pulmonary artery connections in the neonatal period. Semin. Thorac. Cardiovasc. Surg. 7(3), 130-132 (1995).
6. Schoen FJ, Levy RJ: Tissue heart valves: current challenges and future research perspectives. J. Biomed. Mater. Res. 47, 439-465, (1999).
7. Doty DB: Aortic valve replacement with homograft and autograft. Sem. Thoracic Cardiovascular Surg. 8(3), 249-258 (1996).
8. Gross L, Kugel MA: Topographic anatomy and histology of the valves in the human heart. Am. J. Pathol. 131(7), 445-456 (1931).
9. Sauren AAHJ, Kuijpers W, Steenhoven AAV, Veldpaus FE: Aortic valve histology and its relation with mechanics: preliminary report. J. Biomech. 13, 97-104 (1980).
10. Schoen FJ: Aortic valve structure-function correlations: role of elastic fibers no longer a stretch of the imagination. J. Heart Valve Dis. 6, 1-6 (1997).
11. Broom N, Christie GW: The structure/function relationship of fresh and glutaraldehyde-fixed aortic valve leaflets. In: Cardiac Bioprostheses: Proceedings of the Second International Symposium. Cohn LH, Gallucci V (Eds). Yorke Medical Books, NY, USA 476-491 (1982).
12. Filip DA, Radu A, Simionescu M: Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ. Res. 59, 310-320 (1986).
13. Mulholland DL, Gotlieb AI: Cell biology of valvular interstitial cells. Can. J. Cardiol. 12, 231-236 (1996).
14. Mulholland DL, Gotlieb AI: Cardiac valve interstitial cells: regulator of valve structure and function. Cardiovasc. Pathol. 6, 167-174 (1997).
15. Della Rocca F, Sartore S, Guidolin D et al.: Cell composition of the human pulmonary valve: a comparative study with the aortic valve - the VESALIO project. Ann. Thorac. Surg. 70, 1594-600 (2000).
16. McDonald P, Wilson JE, McNeill S et al.: The challenge of defining normality for human mitral and aortic valves. Geometrical and compositional analysis. Cardiovasc. Pathol. 11, 193-209 (2002).
17. Courtney T, Sacks MS, Stankus J, Guan J, Wagner WR: Design and analysis of tissue engineering scaffolds that mimic soft tissue mechanical anisotropy. Biomaterials 27, 3631-3638 (2006).
18. Driessen NJ, Bouten CV, Baaljens FP: A structural constitutive model for collagenous cardiovascular tissues incorporating the angular fiber distribution, J. Biomech. Eng. 127, 494-503 (2005).
19. May-Newman K, Yin FC: A constitutive law for mitral valve tissue. J. Biomech. Eng. 120, 38-47 (1998).
20. Weinberg EJ, Kaazempur-Mofrad MR: A large-strain finite element formulation for biological tissues with application to mitral valve leaflet tissue mechanics. J. Biomech. 39, 1557-1561 (2006).
21. Scott MJ, Vesely I: Morphology of porcine aortic valve cusp elastin. J. Heart Valve Dis. 5, 464-471 (1996).
22. Vesely I: The role of elastin in aortic valve mechanics. J. Biomech. 31, 115-123 (1998).
23. Chan KL: Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol. 42, 593-599 (2003).
24. Radamannan NM, Gersh B, Bonow RO: Calcific aortic stenosis: from bench to the bedside - emerging clinical and cellular concepts. Heart 89, 801-805 (2003).
25. Hilbert SL, Verrans VJ: forcine aortic valve bioprostheses: morphologic and functional considerations. J. Long Term Eff. Med. Implants 2, 99-112 (1992).
26. Hibert SL, Barrick MK, Ferrans VJ: Porcine aortic valve bioprostheses: a morphologic comparison of the effects of fixation pressure. J. Blamed Mater. Res. 24, 773 (1990).
27. David TE, Ropchan GC, Butany JW: Aortic valve replacement with stentless porcine bioprostheses. J. Card. Surg. 3, 501 (1998).
28. O'Brien MF, Stafford EG, Gardner MA et al.: Allograft aortic valve replacement: long-term follow-up. Ann. Thorac. Surg. 60(Suppl. 2), S65 (1995).
29. Mair R, Harringer W, Wimmer-Greinecker G et al.: Aortic valve replacement with cryopreserved pulmonary allografts: five years' follow-up. Ann. Thorac. Surg. 60(2 Suppl.), S185 (1995).
30. Osson M, Rosenqvist M, Nilsson J: Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular broblasts in degenerative aortic stenosis. J. Am. Coll. Cardiol. 24, 1664 (1994).
31. Haydock D, Barratt-Boyes B, Macedo T et al.: Aortic valve replacement for active infectious endocarditis in 108 patients: a comparison of freehand allograft valves with mechanical prostheses and bioprostheses. J. Thorac. Cardiovasc. Surg. 103, 130-139 (1992).
32. Caira FC, Stock SR, Gleason TG et al.: Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J. Am. Coll. Cardiol. 47, 1707-1712 (2001).
33. Schoen FJ, Levy RJ, Piehler HR: Pathological considerations in replacement cardiac valves. Cardiovasc. Pathol. 1, 29-52 (1992).
34. Turina J, Hess OM, Turina M, Krayenbuehl HP: Cardiac bioprostheses in the 1990s. Circulation 88, 775-781 (1993).
35. Schoen FJ: Interventional and Surgical Cardiovascular Pathology: Clinical Correlations and Basic Principles. WB Saunders, PA, USA (1989).
36. Lee JM, Boughner DR, Courtman DW: The glutaraldehyde-stabilized porcine aortic valve xenograft. II. Effect of fixation with or without pressure on the tensile visco-elastic properties of the leaflet material. J. Biomed. Mater. Res. 18, 79-98 (1984).
37. Schoen FJ: Pathology of bioprostheses and other tissue heart valve replacements. In: Cardiovascular Pathology (2nd Edition). Silver MD (Ed.) Churchill Livingstone, NY, USA 1547-1605 (1991).
38. Jamieson WR, Munro AI, Miyagishima RT, Allen P, Burr LH, Tyers GF: Carpentier-Edwards standard porcine bioprosthesis: clinical performance to seventeen years. Ann. Thorac. Surg. 60, 999-1006 (1995).
39. Cohn LH, Collins JJ, DiSesa VJ et al.: Fifteen-year experience with 1678 Hancock porcine bioprosthetic heart valve replacements. Ann. Surg. 210, 435-442 (1989).
40. Grunkemeier GL, Jamieson WR, Miller DC, Starr A: Actual versus actual risk of porcine structural valve deterioration. J. Thorac. Cardiovasc. Surg. 108, 709-718 (1994).
41. Schoen FJ, Hobson CE: Anatomic analysis of removed prosthetic heart valves: causes of failure of 33 mechanical valves and 58 bioprostheses, 1980 to 1983. Hum. Pathol. 16, 549-559 (1985).
42. Schoen FJ, Levy RJ: Bioprosthetic heart valve failure: pathology and pathogenesis. Cardiol. Clin. 2, 717-739 (1984).
43. Colli A, Gherli T Mestres CA, Pomar JL: Degeneration of native and tissue prosthetic valve in aortic position: do statins play a role in prevention? Int. J. Card. 116, 144-152 (2007).
44. Levy RJ, Schoen FJ, Levy JT, Nelson AC, Howard SL, Oshry LJ: Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am. J. Pathol. 113, 143-155 (1983).
45. Lupinetti FM, Lemmer JH Jr: Comparison of allografts and prosthetic valves when used for emergency aortic valve replacement for active infective endocarditis. Am. J. Cardiol. 68, 637 (1998).
46. Poirer TE, Pelletier LC, Penerin M, Carrier M: 15-year experierice with the Carpentier-Edwards pericardial bioprosthesis. Ann. Thorac. Surg. 66(Suppl. 6), S57-S61 (1998).
47. Schoen FJ, Levy RJ: Calcification of tissue valve substitutes: progress toward understanding and prevention. Ann. Thorac. Surg. 79, 1072-1080 (2005).
48. Schoen FJ, Tsao JW, Levy RJ: Calcification of bovine pericardium used in cardiac valve bioprostheses: implications for the mechanisms of bioprosthetic tissue mineralization. Am. J. Pathol. 123, 134-145 (1986).
49. Schoen FJ, Levy RJ, Nelson AC, Bernhard WF, Nashef A, Hawley M: Onset and progression of experimental bioprosthetic heart valve calcification. Lab. Invest. 52, 523-532 (1985).
50. Skowasch D, Steinmetz M, Nickenig G, Bauriedel G: Is the degeneration of aortic valve bioprostheses similar to that of native aortic valves? Insight into valvular pathology. Expert Rev. Med. Devices 3(4), 453-462 (2006).
51. Ferrans FJ, Boyce SW, Billingham ME, Jones M, Ishihara T, Roberts WC: Calcific deposits in porcine bioprostheses: structure and pathogenesis. Am. J. Cardiol. 46, 721-734 (1980).
52. Valente M, Bortolotti U, Thiene G: Ultrastructural substratesof dystrophic calcification in porcine bioprosthetic valve failure. Am. J. Pathol. 119, 12-21 (1985).
53. Pahrami F, Bostrom K, Watson K, Demer LL: Role of molecular regulation in vascular calcification. J. Atheroscl. Thromb. 3, 90-94 (1996).
54. Schinke T, McKee MD, Karsenty G: Extracellular matrix calcification: where is the action? Nat. Genet. 21, 150-151 (1999).
55. McKee MD, Nanci A: Osteopontin: an interfacial extra-cellular matrix protein in mineralized tissues. Connect. Tissue Res. 35, 197-205 (1996).
56. Giachelli CM, Scatena M, Wada T: Osteopontin: potential roles in vascular function and dystrophic calcification. J. Bone Miner. Metab. 15, 179-183 (1997).
57. Hauschka PV, Lian JB, Cole DE, Gundberg CM: Osteocalcin and matrix Gla proteins: vitamin K-dependent proteins in bone. Physiol. Rev. 69, 990-1047 (1989).
58. Boskey AL: Matrix proteins and mineralization: an overview. Connect. Tissue Res. 35, 357-363 (1996).
59. Ducy P, Desbois C, Boyce B et al.: Increased bone formation in osteocalcindependent mice. Nature 382, 448-452 (1996).
60. Wada T, McKee MD, Steitz S, Giachelli CM: Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ. Res. 84, 166-178 (1999).
61. Srivatsa SS, Harrity PJ, Maercklein PB et al.: Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J. Clin. Invest. 99, 996-1009 (1997).
62. O'Brien KD, Kuusisto J, Reichenbach DD et al.: Osteopontin is expressed in human aortic valvular lesions. Circulation 92(8), 2163-5168 (1995).
63. Dellgren G, David TE, Raanani E et al.: Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J. Thorac. Cardiovasc. Surg. 124, 146-154 (2002).
64. David TE, Ivanov J, Armstrong S et al.: Late results of heart valve replacement with the Hancock II bioprosthesis. J. Thorac. Cardiovasc. Surg. 121, 268-277 (2001).
65. Skowasch D, Schrempf S, Lentini et al.: Presence of Clamidia pneumoniae and cytomegalovirus in degenerated aortic valves. Z. Kardiol. 91, 290-296 (2002).
66. Skowasch D, Yeghiazaryan K, Schrempf S et al.: Persistence of Clamidia pneumoniae in degenerative aortic valve stenosis indicated by heat shock protein 60 homologues. J. Heart Valve Dis. 12, 68-75 (2003).
67. Skowasch D, Schrempf S, Wernert N et al.: Cells of primarily non-valvular origin in degenerative aortic valve stenosis and bioprostheses. Eur. Heart J. 26, 2576-2580 (2005).
68. Human P, Zilla P: Inflammatory and immune processes: thed neglected villain of bioprosthetic degeneration? J. Long Term Eff. Med. Implants 11, 199-200 (2001).
69. Human P, Zilla P: Characterization of the immune response to valve bioprostheses and its role in primary tissue failure. Ann. Thorac. Surg. 71, 385-388 (2001).
70. Antonini-Canterin F, Zuppiroli A Popescu BA et al.: Effects of statins on the progression of bioprosthetic aortic valve degeneration. Am. J. Cardiol. 92, 1479-1482 (2003).
71. David T, Ivanov J: Is degenerative calcification of the native aortic valve similar to calcification of bbioprosthetic heart valves? J. Thor. Cardiov. Surg. 126(4), 939-941 (2003).
72. Shimizaki Y, Kuraoka S, Takeda F et al.: Mitral valve replacemet for impaired bioprosthesis after 19 years in a patient undergoing steroid treatment. J. Heart Valve Dis. 12, 45-47 (2003).
73. Eism K, Ishibashi-Ueda H, Nakano et al.: Calcific degeneration of bioprosthetic aortic valves in patients receiving steroid therapy: J. Heart Valve Dis. 5, 668-672 (1996).
74. Broom ND: An in vitro study of mechanical fatigue in glutaraldehyde-treated porcine aortic valve tissue. biomaterials 1, 3-8 (1980).
75. Sacks MS, Schoen FJ: Calcification-independent collagen damage In explanted cilinical porcine bioprosthetic heart valves. Trans. Soc. Biomater. 22, 313 (1999).
76. Simionescu D, Simionescu A, Deac R: Detection of remnant proteolytic activities in unimplanted glutaraldehyde-treated bovine pericardium and explanted cardiac bioprostheses. J. Biomed. Mater. Res. 27, 821-829 (1993).
77. Vyavahare N, Ogle M, Schoen FJ et al.: Mechanisms of bioprosthetic heart valve failure: fatigue causes collagen structural denaturation and glycosamitioglycan loss. J. Biomed. Mater. Res. 46, 44-50 (1999).
78. Porat RM, Grunewald M, Globerman A et al.: Specic induction of tie 1 promoter by disturbed ow in atherosclerosis-prone vascular niches and ow-obstructing pathologies. Circ. Res. 94, 394-401 (2004).
79. Butcher JT, Nerem RM: Valvular endothelial cells and the mechanoregulation of valvular pathology. Philos. Trans. R. Soc. Lond. B Biol. Sci. 362, 1445-1457 (2007).
80. Ghaisas NK, Foley JB, O'Briain DS et al.: Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J. Am. Coll. Cardiol. 36, 2257-2262 (2000).
81. Prasad Y, Bhalodkar NC: Aortic sclerosis - a marker of coronary atherosclerosis. Clin. Cardiol. 27, 671-673 (2004).
82. Kaden JJ, Dempe CE, Grobholz R et al.: Interleukin-1β promotes matrix metalloproteinase expression and cell proliferation in calcic aortic valve stenosis. Atherosclerosis 170, 205-211 (2003).
83. Chalajour F, Treede H, Ebrahimnejad A, Lauke H, Reichenspurner H, Ergun S: Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp. Cell Res. 298, 455-464 (2004).
84. Muller AM, Cronen C, Kupferwasser LI, Oelert H, Muller KM, Kirkpatrick CJ: Expression of endothelial cell adhesion molecules on heart valves: up-regulation in degeneration as well as acute endocarditis. J. Pathol. 191, 54-60 (2000).
85. Liu AC, Joag VR, Gotlieb AI: The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171, 1407-1418 (2007).
86. Armstrong EJ, Bischoff J: Heart valve development: endothelial cell signaling and differentiation. Circ. Res. 95, 459-470 (2004).
87. High FA, Epstein JA: The multifaceted role of NOTCH in cardiac development and disease. Nat. Rev. Genet. 9, 49-61 (2008).
88. Mohamed SA, Aherrahrou Z, Liptau H et al.: Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem. Biophys. Res. Commun. 345, 1460-1465 (2006).
89. Garg V, Muth AN, Ransom JF et al.: Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270-274 (2005).
90. Yoder MC, Mead LE, Prater D et al.: Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109, 1801-1809 (2007).
91. Paruchuri S, Yang JH, Aikawa E et al.: Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-2. Circ. Res. 99, 861-869 (2006).
92. Lester W, Rosenthal A, Granton B, Gotlieb AI: Porcine mitral valve interstitial cells in culture. Lab. Invest. 59, 710-719 (1988).
93. Yoshioka M, Yuasa S, Matsumura K et al.: Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat. Med. 12, 1151-1159 (2006).
94. Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA: Valvular myofibroblast activation by transforming growth factor-β: implications for pathological extracellular matrix remodeling in heart valve disease. Cirr. Res. 95, 253-260 (2004).
95. Tamura K, Jones M, Yamada I, Ferrans VJ: Wound healing in the mitral valve. J. Heart Valve Dis. 9, 53-63 (2000).
96. Durbin A, Gotlieb AI: Advances towards understanding heart valve response to injury. Cardiovasc. Pathol. 11, 69-77 (2002).
97. Desmouliere A, Badid C, Bochaton-Piallat ML, Gabbiani G: Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int. J. Biochem. Cell Biol. 29, 19-30 (1997).
98. Jian B, Naruia N, Li QY, Mohler ER 3rd, Levy RJ: Progression of aortic valve stenosis: TGF-β1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann. Thorac. Surg. 75, 457-465 (2003).
99. Mohler ER 3rd, Chawla MK, Chang AW et al.: Identification and characterization of calcifying valve cells from human and canine aortic valves. J. Heart Valve Dis. 8, 25-26 (1999).
100. Kaden JJ, Dempfle CE, Kilic R et al.: Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Exp. Mol. Pathol. 78, 36-40 (2005).
101. Shao JS, Cai J, Towler DA: Molecular mechanisms of vascular role of matrix metalloproteinases and their tissue inhibitors. Eur. Heart J. 26, 1333-1341 (2005).
102. O'Brien KD: Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler. Thromb. Visc. Biol. 26, 1721-1728 (2006).
103. Hilbert SL, Sword LC, Batchelder KF et al.: Simultaneous assessment of bioprosthetic heart valve biomechanical properties and collagen crimp length. J. Biomed Mater. Res. 314, 503-509 (1996).
104. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association: Task Force on Practice Guidelines (Committee on Management of Patients with Vaivular Heart Disease). J. Am. Coll. Cardiol. 32, 1486 (1998).
105. Flomenbaum MA, Schoen FJ: Effects of fixation back pressure and antimineralization treatment on the morphology of porcine aortic bioprosthetic valves. J. Thorac. Cardiovasc. Surg. 105, 154-164 (1993).
106. Kasimir MT, Rieder E, Seebacher G et al.: Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J. Heart Valve Dis. 15, 278-286; discussion 286 (2006).
107. Meyer SR, Nagendran J, Desai LS et al.: Decellularization reduces the immune response to aortic valve allografts in the rat. J. Thorac. Cardiovasc. Surg. 130, 469-476 (2005).
108. Hilbert SL, Yanagida R, Souza J et al.: Prototype anionic detergent technique used to decellularize allograft valve conduits evaluated in the right ventricular outflow tract in sheep. J. Heart Valve Dis. 13, 831-840 (2004).
109. David TE: Aortic Valve Repair and Aortic Valve Sparmff Operations in Cardiac Suroery in the Adult. Cohn LH, Edmunds LH Jr (Eds). McGraw-Hill, NY, USA 811-824 (2003).
110. Sodian R, Loebe M, Hein A et al.: Application of stereolithography for scaffold fabrication for tissue engineered heart valves. ASAIO J. 48, 12-16 (2002).
111. Chester A, Taylor PM: Molecular and functional characteristics of heart-valve interstitial cells. Phil. Trans. R. Soc. B 362, 1437-1443 (2007).
112. Kim SS Lim SH, Hong YS et al.: Tissue engineering or heart valves in vivo using bone marrow-derived cells. Artif. Organs 30, 554-557 (2006).
113. Engelmayr GCJ, Hildebrand DK, Sutherland FW et al.: Novel bioreactor for the dynamic flexural stimulation of tissue engineered heart valve biomaterials. Biomaterials 24, 2523-2532 (2003).
114. Barron V, Lyons E, Stenson-Cox C et al.: Bioreactors for cardiovascular cell and tissue growth: a review. Ann. Biomed. Eng. 31, 1017-1030 (2003).
115. Hoerstrup SP, Sodian R, Sperling JS et al.: New pulsatile bioreactor for in vitro formation of tissue engineered heart valves. Tissue Eng. 6, 75-79 (2000).
116. Mol A Bouten CV, Zund G et al.: The relevance of large strains in functional tissue engineering of heart valves. Thorac. Cardiovasc. Surg. 51, 78-83 (2003).
117. Mol A Driessen NJ, Rutten MC et al.: Tissue engineering of human heart valve leaflets: a novel bioreactor for a strain-based conditioning approach. Ann. Biomed Eng. 33, 1778-1788 (2005).
118. Zund G, Breuer CK, Shinoka T et al.: The in vitro construction of a tissue engineered bioprosthetic heart valve. Eur. J. Cardiothorac. Surg. 11 (3), 493-497 (1997).
119. Hubbell JA, Massia SP, Desai NP, Drumheller PD: Endothelial cell-selective materials for tissue engineering in the vascular graft via a new receptor. Biotechnology 9(6), 568-572 (1991).
120. Zisch AH, Lutolf MP, Ehrbar M et al.: Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth. Faseb J. 17(15) 2260-2262 (2003).
121. Shinoka T, Ma PX, Shum-Tim D et al.: Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation 94(Suppl. 9), 1164-1168 (1996).
122. Badylak SF: The extra-cellular matrix as a scaffold for tissue reconstruction. Semin. Cell Dev. Bio. 13(5), 377-383 (2002).
123. Seyer JM, Kang AH: Connective tissue of the subendothelium. In: Vascular Medicine - A Textbook of Vascular Biology and Diseases. Loscalzo J, Creager MA, Dzan VJ (Eds). Little Brown and Company, MA, USA 2-67 (1996).
124. Balley MT, Pillarisetti S, Xiao H et al.: role of elastin in pathologic calcification of xenograft heart valves. J. Biomed Mater. Res. A 66(1), 93-102 (2003).
125. Long JL, Tranquillo RT: Elastic fiber production in cardiovascular tissue-equivalents: matrix biology 22, 339-350 (2003).
126. Wilson F1, Klement P, Lee JM, Coutmant DW: Acellular matrix allograft small caliber vascular prostheses. ASAIO Trans. 36, M340-M343 (1990).
127. Wilson Gj, Courtman DW, Klement P, Lee JM, Yeger H: Acellular matrix: a biomaterial approach for coronary artery bypass ad heart valve replacement. Ann. Thorac. Surg. 60(Suppl. 2), 353-358 (1995).
128. Allaire E, Bruneval P Mandet C, Becquemin JP, Michel B: The immunogenicity of ECM in arterial xenograft. Surgery 122, 73-80 (1997).
129. Courtman DW, Errett BF, Wilson GJ: The role of cross-linking in modification of the immune response elicited against xenogenic vascular acellular matrices. J. Biomed Mater. Res. 55, 576-586 (2001).
130. Bader A, Schilling T, Teebken OE et al.: TIssue engineering of the heart valves - human endothelial cell seeding of detergent acellularized porcine valves. Eur. J. Cardiothor. Surg. 14(3), 279-284 (1998).
131. Zeltinger J, Landeen LK, Alexander HG, Kidd ID, Sibanda B: Development and characterization of tissue engineered aortic valve. Tissue Eng. 7(1), 9-22 (2001).
132. Dohnien PM, Ozaki S, Verbeken E, Yperman J, Flameng W, Konertz WF: Tissue engineering of an auto-xenograft pulmonary heart valve. Asian Cardiovasc. Thorac. Ann. 10(1), 25-30 (2002).
133. Bader A, Steinhoff G, Strobl K: Engineering of human vascular aortic tissue based on a xenogenic starter matrix. Transplantation 70, 7-14 (2000).
134. Neuenschwander S, Hoestrup SP: Heart valve tissue engineering. Transpl. Immunol. 12, 359-365 (2004).
135. Lehner G. Fischlein T, Baretton G. Murphy JG, Reichart B: Endothelialized biological heart valve prostheses in the non human primate model. Eur. J. Cardiothorac. Surg. 11(3), 498-504 (1997).
136. Trantina-Yates AE, Human P, Bracher M, Zilla P: Mitigation of bioprosthetic heart valve degeneration through biocompatibility: in vitro vs. spontaneous endothelialization. Biomaterials 22(13) 1837-1846 (2001).
137. Shinoka T, Breuer CK, Tanel RE et al.: Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann. Thorac. Surg. 60(Suppl. 6), S513-S516 (1995).
138. Sodian R, Sperling JS, Martin DP et al.: Fabrication or a trileaflet heart valve scaffold from a polyhydroxyalkanoate biopoliester for use in tissue engineering. Tissue Eng. 6(2) 183-188 (2000).
139. Sodian R, Hoerstrup SP, Sperling JS et al.: Early in vivo experience with tissue-engineered trileaflet heart valve. Circulation 102(19 Suppl. 3), III22-III29 (2000).
140. Sodian R, Hoerstrup SP, Sperling JS et al.: Evaluation of biodegradable, three-dimensional matrices for tissue engineering of heart valves. ASAIO J. 46(1), 107-110 (2000).
141. Niklason LE, Langer RS: Advances in tissue engineering of blood vessels and other tissues. Transpl. Immunol. 5(4), 303-306 (1997).
142. Niklason LE, Gao, J, Abbott WM et al.: Functional arteries grown in vitro. Science 284(5413), 489-493 (1999).
143. Hoerstrup SP, Sodian R, Daebritz S et al.: Functional living trileaflet heart valves grown in vitro. Circulation 102(19 Suppl. 3), III44-III49 (2000).
144. Hoerstrup SP, Kadner A, Melnitchouk S et al.: Tissue engineering of functional trileaflet heart valves from human marrow stronial cells. Circulation 106(12 Suppl. 1), I143-I150 (2002).
145. Van Lieshout M, Peters G, Rutten M, Baaijens F: A knitted, fibrin-covered polycaprolactone scaffold for tissue engineering of the aortic valve. Tiss. Eng. 12(3), 481-7 (2006).
146. Hoerstrup SP, Zund G, Schoeberlein A, Ye Q, Vogt PR, Turina MI: Fluorescence activated cell sorting: a reliable method in tissue engineering of a bloprosthetic heart valve. Ann. Thorac. Surg. 66(5), 1653-1657 (1998).
147. Schnell AM, Hoerstrup SP, Zund G et al.: Optimal cell source for cardiovascular tissue engineering: venous vs. aortic human myofibroblasts. Thorac. Cardiovasc. Surg. 49(4), 221-225 (2001).
148. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309), 71-74 (1997).
149. Kadner A, Hoerstrup SP, Zund G et al.: A new source for cardiovascular tissue engineering: human bone marrow stromal cells. Eur. J. Cardiothorac. Surg. 21(6), 1055-1060 (2002).
150. Perry TE, Kaushal S, Sutherland FW et al.: Thoracic Surgery Directors Association Award. Bone marrow as a cell source for tissue engineering heart valves. Ann. Thorac. Surg. 75(3) 761-767 (2003).
151. Heorstrup SP, Kadner A, Breymann C et al.: Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann. Thorac. Surg. 74, 46-52 (2002).
152. Sodian R, Lueders C, Kraemer L et al.: Tissue engineering of autologous human heart valves using cryopreserved vascular umbilical cord cells. Ann. Thorac. Surg. 81(6), 2207-2216 (2006).
153. Demir R, Kosanke G, Kohnen G, Kertschanska S, Kaufmann P: Classification of human placental stem villi: review of structural and functional aspects. Microsc. Res. Tech. 38, 29-41 (1997).
154. Aboagye-Mathiesen G, Laugesen J, Zdravkovic M, Ebbesen P: Isolation and characterization of human placental trophoblast subpopulations from first trimester chorionic villi. Clin. Diagn. Lab. Imm. 3(1) 14-22 (1996).
155. Rhoads GG, Jackson LG, Schlesselmann SE et al.: The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic anomalies. N. Engl. J. Med. 320, 609-617 (1989).
156. Sctunicit D, Mol A, Breymarm C et al.: Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation 114(Suppl. 1), 1125-1131 (2006).
157. Hoerstrup SP, Sodian R, Daebritz S et al.: Functional living trileaflet heart valves grown in vitro. Circulation 102(Suppl.), III44-III49 (2000).
158. Narita Y, Hata K, Kagarni H, Usui A, Ueda M, Ueda Y: Novel pulse duplicating bioreactor system for tissue-engineered vascular construct. Tissue Eng. 10, 1224-1233 (2004).
159. Sodian R, Lemke T, Fritsche C et al.: Tissue engineering bioreactors: a new combined cell-seeding and perfusion system for vascular tissue engineering. Tissue Eng. 8, 863-870 (2002).
160. Stegemarm JP, Nerem RM: Phenotype modulation in vascular tissue engineering using biochemical and mechanical stimulation Ann. Biomed. Eng. 31, 391-402 (2003).
161. Mendelson K, Schoen FJ: Heart valve tissue engineering: concepts, approaches, progress and challenges. Ann. Biomed. Eng. 34(12), 1799-1819 (2006).